PT Bundamedik Tbk operates as an Indonesia-based healthcare service provider specializing in hospital management and related medical services. The company offers comprehensive healthcare solutions through its network of facilities, including Bunda Jakarta Woman and Children Hospital, Bunda Jakarta General Hospital, Bunda Margonda General Hospital, Bunda Padang General Hospital, Bunda Ciputat Woman and Children Hospital, Bunda Citra Harapan General Hospital, AZ Zahra Woman and Children Hospital, Bunda Denpasar Woman and Children Hospital; BIC Pacific Place and BIC Vida Bekasi clinics; Morula IVF Indonesia for in vitro fertilization and reproductive sciences via IRSI; Diagnos laboratories for genomics, clinical pathology, radiology, and diagnostic services; Prima Dental Medika for dental care; Bunda Global Pharma for pharmaceutical wholesale and distribution; emergency response services; BMHS Diklat Indonesia for health education and training; and Indonesian Medical Tourism Board (IMTB) initiatives, alongside management consulting for physiotherapy, reproductive technology, oncology, cardiovascular care, and corporate health services. PT Bundamedik Tbk conducts operations across multiple cities in Indonesia, targeting maternal and child health, general medical care, fertility treatments, and specialized diagnostics for individual patients, families, and corporate clients. Founded in 1961 by Dr. Rizal Sini as a maternity clinic and headquartered at Jl. Teuku Cik Ditiro No. 28, Menteng, Jakarta Pusat, the company functions as a subsidiary of PT Bunda Investama Indonesia. In recent developments, PT Bundamedik Tbk acquires a 99.99% stake in PT Medika Sejahtera Bersama (MSB) for IDR 38.99 billion through a share transfer agreement signed on January 31, 2025, with payment in cash to enhance integrated maternal and child hospital services and market share; discloses affiliated transactions including guarantees to subsidiary PT Morula Indonesia in early 2025; faces a IDR 5 billion fine from Indonesia's competition authority in September 2024 for late notification of its 2021 acquisition of 99% in PT Pintu Ilmu; and pursues synergies via partial ownership in PT Morula Indonesia alongside entities like PT Bunda Ipiti Investama and Jinxin Life Asia Healthcare Investment Group.